# A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia

> **NCT00650871** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Sleep Initiation and Maintenance Disorders

## Interventions

- **DRUG:** GW679769
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00650871
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07-30
- **Primary completion:** 2005-08-30
- **Final completion:** 2005-08-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650871, "A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00650871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*